- Home
- PLSE
as of 03-12-2026 2:15pm EST
$21.12
+$1.10
+5.52%
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 1.5B | IPO Year: | 2015 |
| Target Price: | $22.00 | AVG Volume (30 days): | 323.0K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.56 - $26.30 | Next Earning Date: | 06-01-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 912.86% | Revenue Growth (next year): | 259.66% |
| P/E Ratio: | -13.34 | Index: | N/A |
| Free Cash Flow: | -54437000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Pulse Biosciences Inc (DE) (PLSE)
Danahy Kevin Patrick
Sell
Chief Commercial Officer
PLSE Feb 18, 2026
Avg Cost/Share
$23.64
Shares
5,000
Total Value
$118,200.00
Owned After
43,298
SEC Form 4
Danahy Kevin Patrick
Sell
Chief Commercial Officer
PLSE Feb 17, 2026
Avg Cost/Share
$23.63
Shares
20,000
Total Value
$472,600.00
Owned After
43,298
SEC Form 4
Danahy Kevin Patrick
Sell
Chief Commercial Officer
PLSE Feb 13, 2026
Avg Cost/Share
$23.53
Shares
20,000
Total Value
$470,600.00
Owned After
43,298
SEC Form 4
Danahy Kevin Patrick
Sell
Chief Commercial Officer
PLSE Feb 12, 2026
Avg Cost/Share
$23.37
Shares
20,000
Total Value
$467,400.00
Owned After
43,298
SEC Form 4
Danahy Kevin Patrick
Sell
Chief Commercial Officer
PLSE Feb 11, 2026
Avg Cost/Share
$25.20
Shares
20,000
Total Value
$504,000.00
Owned After
43,298
SEC Form 4
Danahy Kevin Patrick
Sell
Chief Commercial Officer
PLSE Feb 10, 2026
Avg Cost/Share
$23.52
Shares
20,000
Total Value
$470,400.00
Owned After
43,298
SEC Form 4
Danahy Kevin Patrick
Sell
Chief Commercial Officer
PLSE Feb 9, 2026
Avg Cost/Share
$21.45
Shares
20,000
Total Value
$429,000.00
Owned After
43,298
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Feb 18, 2026 | Sell | $23.64 | 5,000 | $118,200.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Feb 17, 2026 | Sell | $23.63 | 20,000 | $472,600.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Feb 13, 2026 | Sell | $23.53 | 20,000 | $470,600.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Feb 12, 2026 | Sell | $23.37 | 20,000 | $467,400.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Feb 11, 2026 | Sell | $25.20 | 20,000 | $504,000.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Feb 10, 2026 | Sell | $23.52 | 20,000 | $470,400.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Feb 9, 2026 | Sell | $21.45 | 20,000 | $429,000.00 | 43,298 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 19, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 19, 2026 · 100% conf.
AI Prediction BUY
1D
+10.29%
$27.66
5D
+13.88%
$28.56
20D
+37.06%
$34.38
Price: $25.08 Prob +5D: 100% AUC: 1.000
0001437749-26-004739
plse20251122_8k.htm
false 0001625101
0001625101
2026-02-19 2026-02-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 19, 2026
Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
001-37744
46-5696597
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share
PLSE
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On February 19, 2026, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter and full year ended December 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number
Description
99.1
Press Release issued by Pulse Biosciences, Inc. dated February 19, 2026 - Business Update and Financial Results
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PULSE BIOSCIENCES, INC.
Date: February 19, 2026
By:
/s/ Jon Skinner
Jon Skinner
Chief Financial Officer
(Principal Financial Officer)
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001437749-25-033348
plse20250826_8k.htm
false 0001625101
0001625101
2025-11-05 2025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 5, 2025
Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
001-37744
46-5696597
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share
PLSE
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On November 5, 2025, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter ended September 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number
Description
99.1
Press Release issued by Pulse Biosciences, Inc. dated November 5, 2025 - Business Update and Financial Results
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PULSE BIOSCIENCES, INC.
Date: November 5, 2025
By:
/s/ Jon Skinner
Jon Skinner
Chief Financial Officer
(Principal Financial Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 12, 2025
0001437749-25-026195
plse20250604_8k.htm
false 0001625101
0001625101
2025-08-12 2025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 12, 2025
Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
001-37744
46-5696597
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share
PLSE
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On August 12, 2025, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter ended June 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number
Description
99.1
Press Release issued by Pulse Biosciences, Inc. dated August 12, 2025 - Business Update and Financial Results
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PULSE BIOSCIENCES, INC.
Date: August 12, 2025
By:
/s/ Jon Skinner
Jon Skinner
Chief Financial Officer
(Principal Financial Officer)
Latest Pulse Biosciences Inc (DE) News
PLSE Breaking Stock News: Dive into PLSE Ticker-Specific Updates for Smart Investing
MT Newswires
Pulse Biosciences Begins Enrollment for nPulse System Feasibility Study in Thyroid Cancer
📊
AI Sentiment
Positive
6/10
Compare PLSE vs Leading Stocks
See how PLSE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PLSE Pulse Biosciences Inc (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.